LILRB1/CD85j/ILT2 蛋白, Human (HEK293, Fc)

LILRB1/CD85j/ILT2 Protein is an inhibitory receptor broadly expressed on leukocytes. LILRB1 recognises a wide range of classical HLA-class I allelic variants, as well as the non-classical molecules HLA-F and -G by binding to the conserved a3 domain. LILRB1 also recognises the human CMV-encoded MHC class I homologue UL18. LILRB1 is encoded within the leukocyte receptor complex on 19q13.4. LILRB1 can function as a negative regulator of BiTE molecule-induced tumor cell killing. LILRB1 acts as a novel checkpoint inhibitory molecule capable of restricting BiTE molecule-mediated CD8+ T cell effector function^[1][2][3][4]. LILRB1/CD85j/ILT2 Protein, Human (HEK293, Fc) is the recombinant human-derived LILRB1/CD85j/ILT2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of LILRB1/CD85j/ILT2 Protein, Human (HEK293, Fc) is 435 a.a., with molecular weight of 100-120 kDa.

LILRB1 结合 MHC I 类，还含有基于免疫受体酪氨酸的抑制基序，参与细胞内抑制信号转导，这使它们成为 MHC I 类介导的吞噬作用抑制的有力候选者^[1]。
LILRB1 和 PD1 在 CD8+ TEM 和 TEMRA 亚群中显示出不重叠的表达模式，并且阻断这两种途径可协同增强 CD8+ T 细胞功能。LILRB1 由 CD8+ TEMRA 子集高度表达，这是 BiTE 分子诱导毒性最有效的群体。表达 LILRB1 的 CD8+ T 细胞浸润实体瘤。LILRB1 阻断可增加体外 CD8+ T 细胞的溶细胞活性^[3]。

Human

HEK293

C-hFc

D9IDM8 (G24-H458)

10859

GHLPKPTLWAEPGSVITQGSPVTLRCQGGQETQEYRLYREKKTAPWITRIPQELVKKGQFPIPSITWEHAGRYRCYYGSDTAGRSESSDPLELVVTGAYIKPTLSAQPSPVVNSGGNVTLQCDSQVAFDGFILCKEGEDEHPQCLNSQPHARGSSRAIFSVGPVSPSRRWWYRCYAYDSNSPYEWSLPSDLLELLVLGVSKKPSLSVQPGPIVAPEETLTLQCGSDAGYNRFVLYKDGERDFLQLAGAQPQAGLSQANFTLGPVSRSYGGQYRCYGAHNLSSEWSAPSDPLDILIAGQFYDRVSLSVQPGPTVASGENVTLLCQSQGWMQTFLLTKEGAADDPWRLRSTYQSQKYQAEFPMGPVTSAHAGTYRCYGSQSSKPYLLTHPSDPLELVVSGPSGGPSSPTTGPTSTSGPEDQPLTPTGSDPQSGLGRH

100-120 kDa

Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.